Study | Country | Groups | Patients (n) | Median age (year) | Stage | Treatment line | EGFRmutations | Adenocarcinoma (%) | Design | Quality (score) | |
---|---|---|---|---|---|---|---|---|---|---|---|
2010 | Kim [19] | Korea | G vs. E | 171/171 | 58/59 | IIIb, IV | 2, 3 | – | 86 | RS | 7 |
2010 | Hotta [20] | Japan | G vs. E | 330/209 | 68/68 | II-IV or recurrent | 2, 3 | – | 76 | RS | 9 |
2010 | Hong [21] | Keroa | G vs. E | 20/17 | 61/67 | IIIb, IV | 2, 3 | – | 75 | RS | 7 |
2011 | Wu [22] | Taiwan | G vs. E | 440/276 | 67/67 | IIIb, IV | 1 or later | Partial | 85 | RS | 9 |
2011 | Shin [12] | Keroa | G vs. E | 100/82 | 65/65 | III, IV | 2 | Partial | 0 | RS | 7 |
2011 | Togashi [23] | Japan | G vs. E | 85/69 | 65/68 | IIIb, IV | 1 or later | Partial | 82 | RS | 8 |
2011 | Fan [14] | Taiwan | G vs. E | 715/407 | – | IIIb, IV | 1 or later | Partial | 77 | RS | 8 |
2011 | Jung [24] | Korea | G vs. E | 72/51 | 55/55 | IIIb, IV | 1 or later | Partial | 59 | RS | 6 |
2012 | Wu [25] | Taiwan | G vs. E | 124/100 | – | IIIb, IV | 1 or later | Partial | 100 | RS | 8 |
2012 | Kim [26] | Keroa | G vs. E | 48/48 | 59/60 | IIIb, IV | 2 | Partial | 91 | RCT | 4 |
2012 | Suzumura [27] | Japan | G vs. E | 232/86 | 67/66 | IIIb, IV | – | Partial | 95 | RS | 8 |
2013 | Yoshida [28] | Japan | G vs. E | 107/35 | 64/67 | III, IV or recurrent | 1 or later | Partial | 84 | RS | 8 |
2013 | Shao [29] | Taiwan | G vs. E | 655/329 | 61/63 | IIIb, IV or recurrent | 3 | – | 80 | RS | 9 |
2013 | Lee [30] | Korea | G vs. E | 11/14 | 49/58 | IV | 1 or later | Partial | 92 | RS | 8 |
2013 | Yu [31] | China | G vs. E | 16/22 | 54/52 | – | 3 | Partial | 100 | RS | 8 |
2014 | Lim [32] | Korea | G vs. E | 121/121 | 58/58 | IIIb, IV | 1 or later | All | 98 | RS | 9 |
2014 | Sato [13] | Japan | G vs. E | 213/69 | 66/66 | IIIb, IV or recurrent | – | Partial | 86 | RS | 8 |
2014 | Lin [33] | China | G vs. E | 57/24 | – | IIIb, IV | 1 | All | 59 | RS | 7 |
2014 | Ren [34] | China | G vs. E | 60/142 | 59/59 | IV | 1 or later | Partial | 66 | RS | 8 |
2014 | Li [35] | China | G vs. E | 53/97 | 59/59 | IIIb, IV | 2 | Partial | 67 | RS | 8 |
2014 | Takeda [36] | Japan | G vs. E | 57/11 | 69/69 | III, IV or recurrent | 1 or later | All | 99 | RS | 6 |
2015 | Otsuka [37] | Japan | G vs. E | 35/9 | 70/62 | IIIb, IV | 1 or later | All | 91 | RS | 9 |
2015 | Song [38] | China | G vs. E | 37/65 | 75/75 | IIIb, IV | 2 or later | Partial | 83 | RS | 7 |
2015 | Koo [39] | Korea | G vs. E | 166/56 | – | IV | 1, 2, 3 | All | 87 | RS | 7 |
2016 | Ruan [40] | China | G vs. E | 63/134 | 59/60 | III, IV | – | All | – | RS | 8 |
2016 | Hirano [41] | Japan | G vs. E | 10/16 | 71/71 | IB-IV or recurrent | – | All | 81 | RS | 8 |
2016 | Urata [10] | Japan | G vs. E | 279/280 | 68/67 | IIIb, IV or recurrent | 2, 3 | Partial | 100 | RCT | 5 |
2016 | Suh [42] | Korea | G vs. E | 146/5 | 65/65 | IIIb, IV | 1 | All | 97 | RS | 7 |
2016 | Kashima [43] | Japan | G vs. E | 52/11 | 68/68 | IV | – | All | – | RS | 8 |
2017 | Yang [11] | China | G vs. E | 128/128 | – | IIIb, IV | 1, 2 | All | 96 | RCT | 5 |
2017 | Kuan [15] | Taiwan | G vs. E | 304/63 | 65/67 | IIIb, IV | 1 | All | – | RS | 8 |